Orange Book product · Generic (ANDA)
RITONAVIR
RITONAVIR
At a glance
Feb 16, 2024
Approved
Generic (ANDA)
Application
Not listed
TE code
None
Listed patents
Key dates
Approval
FDA approval date of this drug product.
Feb 16, 2024
2 yr 4 mo ago
Today
Pharmaceutical detail
Active ingredient
RITONAVIR
Strength
100MG
Dosage form
CAPSULE
Route
ORAL
TE code
Not listed
Application
ANDA 205024
Product number
001
Marketing status
RX
Reference listed drug (RLD)
No
Reference standard (RS)
No
Active-ingredient family
View full familyGeneric (ANDA) of RITONAVIR
- 2017NORVIRBrand (NDA)
NDA 209512 · ABBVIE
- 2010NORVIRBrand (NDA)
NDA 022417 · ABBVIE
- 1999NORVIRBrand (NDA)
NDA 020945 · ABBVIE
- 1996NORVIRBrand (NDA)
NDA 020680 · ABBOTT
- 1996NORVIRBrand (NDA)
NDA 020659 · ABBVIE
- 2022RITONAVIRGeneric (ANDA)
ANDA 203759 · CIPLA
- 2020RITONAVIRGeneric (ANDA)
ANDA 205801 · HIKMA
- 2018RITONAVIRGeneric (ANDA)
ANDA 208890 · AMNEAL
- 2018RITONAVIRGeneric (ANDA)
ANDA 206614 · AUROBINDO PHARMA LTD
- 2018RITONAVIRGeneric (ANDA)
ANDA 204587 · HETERO LABS LTD III
- 2015RITONAVIRGeneric (ANDA)
ANDA 202573 · CIPLA
Listed patents
No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
